- Home
- ECO vs SCLXW Comparison
ECO vs SCLXW Comparison
Compare ECO & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECO
- SCLXW
- Stock Information
- Founded
- ECO 2018
- SCLXW N/A
- Country
- ECO Greece
- SCLXW United States
- Employees
- ECO N/A
- SCLXW 115
- Industry
- ECO
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- ECO
- SCLXW Health Care
- Exchange
- ECO Nasdaq
- SCLXW Nasdaq
- Market Cap
- ECO N/A
- SCLXW N/A
- IPO Year
- ECO N/A
- SCLXW N/A
- Fundamental
- Price
- ECO $23.72
- SCLXW $0.08
- Analyst Decision
- ECO Strong Buy
- SCLXW
- Analyst Count
- ECO 1
- SCLXW 0
- Target Price
- ECO $40.00
- SCLXW N/A
- AVG Volume (30 Days)
- ECO 114.0K
- SCLXW 4.0K
- Earning Date
- ECO 05-14-2025
- SCLXW 03-07-2025
- Dividend Yield
- ECO 12.65%
- SCLXW N/A
- EPS Growth
- ECO N/A
- SCLXW N/A
- EPS
- ECO 3.38
- SCLXW N/A
- Revenue
- ECO $393,229,831.00
- SCLXW $55,152,000.00
- Revenue This Year
- ECO N/A
- SCLXW N/A
- Revenue Next Year
- ECO $4.00
- SCLXW N/A
- P/E Ratio
- ECO $6.96
- SCLXW N/A
- Revenue Growth
- ECO N/A
- SCLXW 22.02
- 52 Week Low
- ECO $17.91
- SCLXW $0.18
- 52 Week High
- ECO $36.69
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- ECO 58.12
- SCLXW N/A
- Support Level
- ECO $23.44
- SCLXW N/A
- Resistance Level
- ECO $25.25
- SCLXW N/A
- Average True Range (ATR)
- ECO 0.72
- SCLXW 0.00
- MACD
- ECO 0.13
- SCLXW 0.00
- Stochastic Oscillator
- ECO 62.77
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.